Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Genitourinary 2Breast 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Mesothelioma, Malignant 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × Tetrahydrouridine × Clear all
NCT02664181 2024-09-03

PRECISE

Case Comprehensive Cancer Center

Phase 2 Completed
13 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT01479348 2020-06-02

Imaging Study for FdCyd and THU Cancer Treatment

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
5 enrolled 12 charts
BreastGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms

NCT00978250 2019-12-27

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
95 enrolled 15 charts
BreastGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡